Sawula, Evan
Miersch, Shane
Jong, Eric D.
Li, Chengjin
Chou, Fang-Yu
Tang, Jean Kit
Saberianfar, Reza
Harding, Jeffrey
Sidhu, Sachdev S.
Nagy, Andras http://orcid.org/0000-0003-4311-0413
Funding for this research was provided by:
Canada Research Chairs
Natural Sciences and Engineering Research Council of Canada (Canada Graduate Scholarship)
Canadian Institutes of Health Research (COVID-19 Operating Grant OV3-170649, Foundation Grant)
Emergent Ventures/Thistledown Foundation FAST grant
University of Toronto (Medicine by Design, Ontario Graduate Scholarship)
panCELLa Inc.
Emergent Ventures/The Mercatus Center FAST (#2161, #2189)
Temerty Foundation Knowledge Translation Grant-Novel Antibody Tools for COVID-19
Canada Foundation for Innovation Infrastructure and Operating Grant (#IOF-33363)
Article History
Received: 20 February 2023
Accepted: 30 October 2023
First Online: 6 November 2023
Declarations
:
: All animal procedures were performed in compliance with the Animals for Research Act of Ontario and the Guidelines of the Canadian Council on Animal Care. The protocols performed in this study were approved by the Toronto Centre for Phenogenomics Animal Care Committee under the project ‘Feasibility Assessment of Cell-Mediated Passive Immunization Against Foreign Pathogens’ (AUP #24-0365H, approved on 18 Nov 2020).
: Not applicable.
: A.N. is a co-founder of panCELLa Inc. that has exclusive licences for the FailSafe™ and iACT technologies developed by the Nagy lab. A.N. is an inventor of these technologies, and J.H. is an inventor of the iACT technology. All other authors have no competing interests.